ArticleMicrobiology spectrum2026
Clinical performance of the VITEK REVEAL fast antimicrobial susceptibility test within a real-world workflow for gram-negative bacteremia: comparison with QMAC-dRAST and conventional methods.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Direct rapid antimicrobial susceptibility testing (RAST) from positive blood cultures: Recent advances, challenges, and future directions.Practical laboratory medicine · 2026Review
- The impact of multicenter microbiology laboratory workflow optimization on antimicrobial susceptibility testing reporting time and outcomes of patients with bloodstream infection.Frontiers in cellular and infection microbiology · 2026Article
- Evolving microbiology laboratories: mastering automated culture-based processes and molecular assays, an institutional experience.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Fast antimicrobial susceptibility testing (AST) is essential for appropriate antimicrobial therapeutic guidance in patients with bloodstream infections, reducing the time required for optimal treatment. We aimed to evaluate the clinical performance of the VITEK REVEAL (REVEAL), a volatile organic compound-based fast AST system, compared with our already established AST workflow for bloodstream infections. We prospectively collected a total of 107 gram-negative isolates from positive blood cultures and performed rapid species identification using the BIOFIRE BCID2 panel, followed by AST using the REVEAL system. We conducted parallel comparative tests (QMAC-dRAST, VITEK 2, and ETEST for selected antimicrobials) and analyzed the results for categorical agreement (CA), essential agreement (EA), and categorical discrepancies. Moreover, we compared the time to results between the REVEAL vs QMAC-dRAST and VITEK2. Compared with QMAC-dRAST, REVEAL demonstrated 94.1% CA and 98.4% EA across 1,200 pairwise comparisons, with very major discrepancy (VMD) and major discrepancy (MD) rates of 1.4% and 0.7%, respectively. Compared to VITEK2 (872 comparisons), REVEAL yielded 94.5% CA and 97.9% EA, with VMD and MD of 0.5% and 0.6%, respectively. For ceftazidime/avibactam and ceftolozane/tazobactam, REVEAL showed 100% and 98.6% CA, respectively, compared to ETEST. The median final and per-antibiotic time to results for REVEAL were 8.00 h (range: 6.50-8.15 h) and 5.97 h (range: 3.17-8.15 h), respectively. The REVEAL system demonstrated high concordance with existing fast and conventional AST methods and enabled reliable susceptibility testing. These results support the potential integration of the REVEAL system into routine microbiological workflows for time-sensitive clinical decision-making in bloodstream infections. IMPORTANCE: Fast antimicrobial susceptibility testing is critical for initiating appropriate therapy in patients with gram-negative bacteria-induced bloodstream infections. Conventional antimicrobial susceptibility testing methods often require extended turnaround times, thereby delaying optimal treatment. In this study, we prospectively evaluated the VITEK REVEAL system, which detects bacterial growth-associated volatile organic compounds to directly determine antimicrobial susceptibility in positive blood cultures. We assessed the system against our already established identification and antimicrobial susceptibility testing methods, including both fast and conventional platforms currently implemented in routine clinical practice. The volatile organic compounds-based system demonstrated high concordance, shorter time-to-results, and reliable performance for newer antimicrobial agents. By directly comparing its performance with established clinical diagnostic tools, this study provides relevant support for the potential integration of this approach into real-world laboratory workflows, with implications for improved patient management and antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.